Cancer immunotherapies have given patients with particularly intractable cancers new hope, but not everyone benefits. One such immunotherapy, known as CAR T-cell therapy, works only in about a third of the people who take it—and the reason may lie in the microbes residing in our guts. Over the next year, a team of Stanford and